

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Pharmacy billing (NDC: _____) Start Date (or date of next dose): _____

Dose: _____ Regimen: _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria

For Initial Authorization (Initial approval will be for the duration of 6 months):

1. Please indicate diagnosis and information:

Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

A. Upfront therapy (including induction and consolidation) in combination with multi-agent chemotherapy or as a single-agent? Yes ___ No ___

B. Maintenance therapy in combination with vincristine and prednisone, with or without methotrexate and mercaptopurine? Yes ___ No ___

C. Maintenance therapy including post-hematopoietic stem cell transplant? Yes ___ No ___

D. Relapsed/refractory as a single-agent or in combination with multi-agent chemotherapy? Yes ___ No ___

Chronic Myeloid Leukemia (CML)

A. Chronic, accelerated, or blast phase CML? Yes ___ No ___

B. Post-hematopoietic stem cell transplant? Yes ___ No ___

Soft Tissue Sarcoma – Gastrointestinal Stromal Tumors (GIST)

A. Progressive disease and failed imatinib, sunitinib, or regorafenib? Yes ___ No ___

B. PDGFRA D842V mutation? Yes ___ No ___

Other, please provide diagnosis: _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on dasatinib? Yes ___ No ___

3. Has the member experienced adverse drug reactions related to dasatinib therapy? Yes ___ No ___

If yes, please specify adverse reactions: _____

Additional Information: _____

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit

Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.